Arrowhead Pharmaceuticals, Inc. (ARWR)
Chart Events
Performance Outlook
| Previous Close | 33.28 |
| Open | 33.29 |
| Bid | 33.60 x 800 |
| Ask | 33.62 x 800 |
| Day's Range | 33.21 - 34.06 |
| 52 Week Range | 26.81 - 56.25 |
| Volume | |
| Avg. Volume | 1,014,980 |
| Market Cap | 3.502B |
| Beta (5Y Monthly) | 1.46 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.00 |
| Earnings Date | Jan 31, 2023 - Feb 06, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 73.92 |
- Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 First Quarter Results
PASADENA, Calif., January 25, 2023--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 6, 2023, at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 first quarter ended December 31, 2022.
- Simply Wall St.
A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Arrowhead...
- Zacks Small Cap Research
ARWR: Encouraging Results for Phase 2 SEQUOIA Trial…
By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT On January 9, 2023, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced topline results for the Phase 2 SEQUOIA trial of fazirsiran (TAK-999/ARO-AAT) for the treatment of alpha-1 antitrypsin deficiency (AATD) liver disease. A copy of the slides discussing the results can be found here . The SEQUOIA trial is a placebo
